Friday, September 30, 2022


Biotechnology News Magazine

Genetron Health Partners with Guizhou Province’s Dafang County to Lead Liver Cancer Early Screening Project

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will work with Guizhou Province’s Dafang County authorities to lead the “Early Screening for Regional Liver Cancer Prevention and Containment Demonstration Project”.

Backed by the Central Committee of the Chinese Peasants and Workers Democratic Party and guided by China’s National Cancer Center, this project is a collective effort that will be carried out by the Dafang County Health Bureau, the People’s Hospital of Dafang, and Genetron Health.

The project seeks to push boundaries for leading cancer early screening technologies, products, and services in China’s rural markets, enabling healthcare efforts to reach a wider range of people. This project represents Genetron Health’s latest efforts to partner with local governments, following the Company’s previous partnership with Wuxi’s Huishan district.

Genetron Health will work with its partners to carry out early screening, diagnosis, treatment, follow-up screenings, and patient management for high risk liver cancer groups in Guizhou’s Dafang County. Genetron Health will establish a comprehensive cancer prevention and containment model that prioritizes prevention, and integrates it with long-term screening management, diagnosis, and treatment.

HCCscreen™, Genetron Health’s blood-based early screening test for hepatocellular carcinoma, will play a key role in this project. HCCscreen™ leverages Genetron Health’s original technology, Mutation Capsule, to simultaneously detect different biomarkers in a blood sample without reducing sensitivity; the technology can also be used repeatedly on the same blood sample. This enables it to obtain more comprehensive, accurate information in a manner that is not only simple, fast, and precise, but is also more accessible for doctors and patients. In 2019, China’s National Cancer Center used HCCscreen™’s liver cancer early screening liquid biopsy technology in a large-scale prospective cohort study. According to the project’s recently released data, HCCscreen™ was able to achieve 88% sensitivity and 93% specificity in a prospective cohort of 1,615 HBsAg positive patients, indicating performance superior to that of studies using ultrasound and AFP detection technology.

“Innovating medical technology begins with exploration, and extrapolating scientific research results to the general public is a core value of independent innovation. In response to the government’s ‘Healthy China 2030’ campaign, we have made extensive efforts to build a three-dimensional cancer prevention and containment system,” said Sizhen Wang, Co-Founder and CEO of Genetron Health.

“On one hand, we act as a driving force, working together with various partners and stakeholders across the value chain to promote the industry’s development. On the other hand, we use original technology to move precise cancer diagnosis forward to the early screening stage, enabling the prevention and containment of cancer across the entire cycle. More importantly, we are able to deeply penetrate local markets and make technology accessible to a wider population, enabling better, more equitable protection of people’s health,” concluded CEO Wang.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine